Evolutionary Advances in the Delivery of Aminosalicylates for the Treatment of Ulcerative Colitis

R. D. Cohen


Aliment Pharmacol Ther. 2006;24(3):465-474. 

In This Article


The current first-line therapy for patients with mild-to-moderate UC is 5-ASA therapy, which has been shown to be efficacious and well tolerated and is likely to remain the mainstay of therapy for this disease. Current delivery mechanisms include oral and rectal (topical) formulations which, while effective in the majority of patients, are associated with a number of limitations, including inconvenient dosing regimens, lack of efficacy in all types of UC and poor patient acceptability. These limitations have led to the evolution of a variety of improved delivery formulations in an effort to improve patient compliance, treat all types of UC and improve overall treatment success. Micropellet formulations and high-dose tablets appear to offer comparable efficacy and tolerability to conventional treatment, although any benefit in terms of patient compliance, particularly in long-term maintenance therapy among patients with quiescent disease, remains to be proven. Novel methods of delivery, such as using MMX technology (MMX mesalazine) designed to provide once-daily dosing in an effective, high-strength tablet formulation, may offer a significant improvement in the therapy of UC.

CLICK HERE for subscription information about this journal.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.